For instance, FASN is crucial in converting glucose into lipids, serving as a central determinant for the hepatic capacity to synthesize fatty acids and functioning as a key regulator in hepatic de novo lipogenesis [58], which is regarded as a promising therapeutic target for both NAFLD and HCC [59, 60]. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.